Ascentage Pharma Group International Crecimiento futuro

Future controles de criterios 3/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Ascentage Pharma Group International de 52.2% y 25.8% por año respectivamente. Se prevé que el BPA crezca en un 53.9% al año. Se espera que la rentabilidad financiera sea de 419.2% en 3 años.

Información clave

52.2%

Tasa de crecimiento de los beneficios

53.9%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	42.7%
Tasa de crecimiento de los ingresos	25.8%
Rentabilidad financiera futura	419.2%
Cobertura de analistas	Low
Última actualización	20 Nov 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Ascentage Pharma Group International's (HKG:6855) Shares Climb 26% But Its Business Is Yet to Catch Up

Sep 04

Here's Why Ascentage Pharma Group International (HKG:6855) Can Afford Some Debt

Aug 26

Ascentage Pharma Group International's (HKG:6855) Shares Climb 29% But Its Business Is Yet to Catch Up

Jun 18

Here's Why Ascentage Pharma Group International's (HKG:6855) CEO May Not Expect A Pay Rise This Year

May 03

Why We're Not Concerned Yet About Ascentage Pharma Group International's (HKG:6855) 30% Share Price Plunge

Mar 30

Are Investors Undervaluing Ascentage Pharma Group International (HKG:6855) By 40%?

Feb 17

There's Reason For Concern Over Ascentage Pharma Group International's (HKG:6855) Price

Dec 20

Ascentage Pharma Group International (HKG:6855) Is Making Moderate Use Of Debt

Oct 28

Some Analysts Just Cut Their Ascentage Pharma Group International (HKG:6855) Estimates

Aug 27

There's Reason For Concern Over Ascentage Pharma Group International's (HKG:6855) Price

Aug 23

Ascentage Pharma Group International (HKG:6855) Is Carrying A Fair Bit Of Debt

Jun 19

Ascentage Pharma Group International (HKG:6855) Has Debt But No Earnings; Should You Worry?

Dec 04

Is Ascentage Pharma Group International (HKG:6855) A Risky Investment?

Aug 30

Does Ascentage Pharma Group International (HKG:6855) Have A Healthy Balance Sheet?

Oct 04

Previsiones de crecimiento de beneficios e ingresos

SEHK:6855 - Estimaciones futuras de los analistas y datos financieros pasados (CNY Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	2,226	713	860	734	5
12/31/2025	511	-894	-854	-727	5
12/31/2024	994	-327	-393	-262	5
6/30/2024	903	-360	-751	-712	N/A
3/31/2024	563	-643	-767	-719	N/A
12/31/2023	222	-926	-783	-726	N/A
9/30/2023	239	-902	-798	-707	N/A
6/30/2023	257	-879	-814	-687	N/A
3/31/2023	233	-881	-852	-671	N/A
12/31/2022	210	-883	-891	-654	N/A
9/30/2022	160	-848	-922	-620	N/A
6/30/2022	111	-812	-954	-586	N/A
3/31/2022	69	-797	-997	-595	N/A
12/31/2021	28	-782	-1,041	-605	N/A
9/30/2021	25	-759	-1,021	-635	N/A
6/30/2021	23	-735	-1,000	-665	N/A
3/31/2021	18	-706	-931	-637	N/A
12/31/2020	12	-678	-861	-610	N/A
9/30/2020	14	-922	-798	-576	N/A
6/30/2020	15	-1,167	-735	-542	N/A
3/31/2020	15	-1,324	-638	-501	N/A
12/31/2019	15	-1,481	-542	-460	N/A
9/30/2019	11	-1,171	-454	-399	N/A
6/30/2019	7	-862	-366	-338	N/A
3/31/2019	7	-604	-310	-288	N/A
12/31/2018	7	-345	-253	-238	N/A
12/31/2017	6	-119	N/A	-108	N/A
12/31/2016	8	-108	N/A	-46	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que 6855 siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que 6855 siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que 6855 siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (25.8% al año) de 6855 crezcan más rápidamente que los del mercado Hong Kong (7.8% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (25.8% al año) de 6855 crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de 6855 sea muy elevada dentro de 3 años (419.2%).

Ascentage Pharma Group International Crecimiento futuro

Future controles de criterios 3/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus revenue estimates increase by 40%

Forecast to breakeven in 2026

Consensus EPS estimates fall by 15%

Consensus revenue estimates fall by 12%

Consensus revenue estimates decrease by 22%, EPS upgraded

Recent updates

Ascentage Pharma Received CDE Clearance for Registrational Phase III Studies of APG-2449 for Treatment of Patients with NSCLC

First half 2024 earnings released: EPS: CN¥0.56 (vs CN¥1.47 loss in 1H 2023)

Ascentage Pharma Group International's (HKG:6855) Shares Climb 26% But Its Business Is Yet to Catch Up

Consensus revenue estimates increase by 40%

Forecast to breakeven in 2026

Here's Why Ascentage Pharma Group International (HKG:6855) Can Afford Some Debt

First half 2024 earnings released: EPS: CN¥0.56 (vs CN¥1.47 loss in 1H 2023)

New major risk - Revenue and earnings growth

Ascentage Pharma Clears to Initiate A Registrational Phase III Study of Lisaftoclax, by the Center for Drug Evaluation of China National Medical Products Administration

Ascentage Pharma Group International to Report First Half, 2024 Results on Aug 22, 2024

New minor risk - Shareholder dilution

Ascentage Pharma Group International's (HKG:6855) Shares Climb 29% But Its Business Is Yet to Catch Up

Ascentage Pharma Announces Updated Results from Three Studies of Olverembatinib (HQP1351)

New minor risk - Share price stability

Ascentage Pharma Group International Announces Board and Committee Changes

Ascentage Pharma Releases Updated Clinical Data of olverembatinib in SDH-Deficient GIST, Including a CBR of 92.3%

Ascentage Pharma Releases Latest Results from Multiple Clinical Studies of Its Lead Drug Candidates in 2024 American Society of Clinical Oncology Annual Meeting

Here's Why Ascentage Pharma Group International's (HKG:6855) CEO May Not Expect A Pay Rise This Year

Consensus EPS estimates fall by 15%

Why We're Not Concerned Yet About Ascentage Pharma Group International's (HKG:6855) 30% Share Price Plunge

Ascentage Pharma Group International, Annual General Meeting, May 10, 2024

Full year 2023 earnings released: CN¥3.28 loss per share (vs CN¥3.35 loss in FY 2022)

Ascentage Pharma Group International to Report Fiscal Year 2023 Results on Mar 27, 2024

Ascentage Pharma to Present Three Preclinical Studies at 2024 American Association of Cancer Research Annual Meeting

Are Investors Undervaluing Ascentage Pharma Group International (HKG:6855) By 40%?

Ascentage Pharma Receives Clearance from the US Food and Drug Administration to Initiate Global Registrational Phase III Trial of Olverembatinib (HQP1351) in Patients with Chronic-Phase Chronic Myeloid Leukemia

Ascentage Pharma Announces Olverembatinib Included in Newest Guidelines on Chronic Myeloid Leukemia (CML) Management from the National Comprehensive Cancer Network (NCCN)

There's Reason For Concern Over Ascentage Pharma Group International's (HKG:6855) Price

Ascentage Pharma Group International Presents Preliminary Results from A Phase II Study of Novel Drug Candidate, Olverembatinib

Ascentage Pharma Group International Releases the First Dataset of BCL-2 Inhibitor Lisaftoclax in Patients with R/R Mm, Demonstrating Encouraging ORR and VGPR

Ascentage Pharma Announces the Launch of Olverembatinib in Newly Approved Indication and the Dispatch of First Batch for the New Indication

China National Medical Products Administration Approves Olverembatinib for Treatment of Cml-Cp Patients

Ascentage Pharma Group International to Present Results from Multiple Clinical Studies of olverembatinib and APG-2575 at the 2023 American Society of Hematology(ASH) Annual Meeting, two of which have been Selected for Oral Reports

Ascentage Pharma Group International (HKG:6855) Is Making Moderate Use Of Debt

Ascentage Pharma Releases Latest Data of Pelcitoclax (Apg-1252) Combined with Osimertinib Demonstrates Potential as A New Treatment Option for Tp53-And Egfr-Mutant Nsclc

Ascentage Pharma Announces First Patient Dosed in the Registrational Phase III Study of Olverembatinib in Treatment-Naïve Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia

Ascentage Pharma Announces Global Registrational Phase III Study of Bcl-2 Inhibitor Lisaftoclax in Treatment Naïve Patients with CLL/SLL Approved by the China CDE

Consensus revenue estimates fall by 12%

Some Analysts Just Cut Their Ascentage Pharma Group International (HKG:6855) Estimates

First half 2023 earnings released: CN¥1.47 loss per share (vs CN¥1.54 loss in 1H 2022)

There's Reason For Concern Over Ascentage Pharma Group International's (HKG:6855) Price

Ascentage Pharma Announces Clearance for Global Registrational Phase III Trial

Ascentage Pharma Group International to Report First Half, 2023 Results on Aug 21, 2023

Ascentage Pharma Group International Receives Clearance from the U.S. Food and Drug Administration to Initiate A Phase 3 Registrational Trial of Lisaftoclax

Ascentage Pharma Group International Announces CDE's Approval for the Phase III Pivotal Study in China of Olverembatinib for the Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ All)

Ascentage Pharma Group International (HKG:6855) Is Carrying A Fair Bit Of Debt

Ascentage Pharma Group International Releases Updated Data Showing APG-2449's Potential as a New Treatment for Drug-Resistant NSCLC

Ascentage Pharma Group International Recommends Breakthrough Therapy Designation in China for the Treatment of Sdh-Deficient GIST

Ascentage Pharma Group International Presents Results from Four Studies at 2023 American Society of Clinical Oncology Annual Meeting

Consensus revenue estimates decrease by 22%, EPS upgraded

Full year 2022 earnings: EPS and revenues miss analyst expectations

Ascentage Pharma Group International has completed a Follow-on Equity Offering in the amount of HKD 550.125 million.

Ascentage Pharma Group International's Third-Generation BCR-ABL Inhibitor Olverembatinib Included into the 2022 National Reimbursement Drug List

Ascentage Pharma Group International Releases Preliminary Results from a Global Phase II Study of Lisaftoclax

Ascentage Pharma Delivers Oral Report on the First Dataset from the US Study of Olverembatinib (HQP1351) with Promising Efficacy Observed in Patients Who Failed Prior Treatment with Ponatinib

Ascentage Pharma Group International (HKG:6855) Has Debt But No Earnings; Should You Worry?

Ascentage Pharma's Global Industrial Base Obtains Drug Production Enterprise License

Ascentage Pharma Group International Announces IND Approval in China for Phase I Study of APG-5918 in Patients with Advanced Solid Tumors or Hematologic Malignancies

Ascentage Pharma Group International Announces Released Results from A Phase I Study of the Investigational Inhibitor of Apoptosis Protein (Iap) Antagonist Apg-1387 in Chinese Patients with Chronic Hepatitis B

Ascentage Pharma Releases Phase I Results of Iap Antagonist Apg-1387 in an Oral Report Showing Potential for Functionally Curing Chb

Co-Founder recently bought HK$159k worth of stock

Ascentage Pharma to Present Data of Olverembatinib (HQP1351) in Three Oral Reports, Including the First Dataset from the First US Study, At the ASH Annual Meeting

Ascentage Pharma to Announce Results from First-in-Human Study of IAP Antagonist APG-1387 in an Oral Report at the AASLD Annual Meeting

Ascentage Pharma Announces Phase I/Ii Data of Olverembatinib (Hqp1351) Published in the Journal of Hematology & Oncology, Further Validating the Drug's Best-In-Class Potential

Is Ascentage Pharma Group International (HKG:6855) A Risky Investment?

First half 2022 earnings released: CN¥1.54 loss per share (vs CN¥1.53 loss in 1H 2021)

Ascentage Pharma Group International to Report Q2, 2022 Results on Aug 26, 2022

High number of new directors

Ascentage Pharma Announces Clinical Trial Application for Olverembatinib (HQP1351) Approved in Canada

Ascentage Pharma Announces China National Medical Products Administration Accepts and Grants Priority Review Designation to Drug Application for Olverembatinib for the Treatment of Drug-Resistant CML